EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting Hsp90α to inhibit HMGB1‐mediated renal inflammation and fibrosis

Huizhi Wei, Jinhong Ren, Xiue Feng, Chengxiao Zhao, Yuanlin Zhang, Hongxia Yuan, Fan Yang, Qingshan Li iD

Cell Proliferation · 2025

DOI: 10.1111/cpr.13774 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Proliferation, 2025. Verfasst von Huizhi Wei und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Medicinal Basic Research Innovation Center of Chronic Kidney Disease, Ministry of Education, Shanxi Medical University, Taiyuan, …. Hauptthemen laut MEDLINE: HMGB1 Protein, HSP90 Heat-Shock Proteins, Inflammation, Kidney. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Major Science and Technology Projects of China, Shanxi Provincial Key Research and Development Project, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Renal fibrosis, a terminal manifestation of chronic kidney disease, is characterized by uncontrolled inflammatory responses, increased oxidative stress, tubular cell death, and imbalanced deposition of extracellular matrix. 5,2′‐Dibromo‐2,4′,5′‐trihydroxydiphenylmethanone (LM49), a polyphenol derivative synthesized by our group with excellent anti‐inflammatory pharmacological properties, has been identified as a small‐molecule inducer of extracellular matrix degradation. Nonetheless, the protective effects and mechanisms of LM49 on renal fibrosis remain unknown. Here, we report LM49 could effectively alleviate renal fibrosis and improve filtration function. Furthermore, LM49 significantly inhibited macrophage infiltration, pro‐inflammatory cytokine production and oxidative stress. Interestingly, in HK‐2 cells induced by tumour necrosis factor alpha under oxygen–glucose‐serum deprivation conditions, LM49 treatment similarly yielded a reduced inflammatory response, elevated cellular viability and suppressed cell necrosis and epithelial‐to‐mesenchymal transition. Notably, LM49 prominently suppressed the high‐mobility group box 1 (HMGB1) expression, nucleocytoplasmic translocation and activation. Mechanistically, drug affinity responsive target stability and cellular thermal shift assay confirmed that LM49 could interact with the target heat shock protein 90 alpha family class A member 1 (Hsp90α), disrupting the direct binding of Hsp90α to HMGB1 and inhibiting the nuclear export of HMGB1, thereby suppressing the inflammatory response, cell necrosis and fibrogenesis. Furthermore, molecular docking and molecular dynamic simulation revealed that LM49 occupied the N‐terminal ATP pocket of Hsp90α. Collectively, our findings show that LM49 treatment can ameliorate renal fibrosis through inhibition of HMGB1‐mediated inflammation and necrosis via binding to Hsp90α, providing strong evidence for its anti‐inflammatory and anti‐fibrotic actions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HMGB1 ProteinHSP90 Heat-Shock ProteinsInflammationKidneyFibrosisAnimalsHumansMiceMaleEpithelial-Mesenchymal TransitionCell LineMice, Inbred C57BLMolecular Docking SimulationOxidative StressAnti-Inflammatory Agents

Substanzen

HMGB1 ProteinHSP90 Heat-Shock ProteinsAnti-Inflammatory Agents

Autor:innen und Institutionen

  • School of Pharmacy, Medicinal Basic Research Innovation Center of Chronic Kidney Disease, Ministry of Education, Shanxi Medical University, Taiyuan, China.
  • Shanxi Key Laboratory of Innovative Drug for the Treatment of Serious Diseases Basing on the Chronic Inflammation, Shanxi University of Chinese Medicine, Taiyuan, China.

ORCID-Profile: Qingshan Li

Förderung

  • National Major Science and Technology Projects of China
  • Shanxi Provincial Key Research and Development Project
  • National Natural Science Foundation of China
  • Natural Science Foundation of Shanxi Province
  • Shanxi Medical University Project
  • Shanxi Leader Team of Medical Science and Technology Innovations

Zitieren

APA

Wei, H., Ren, J., Feng, X., Zhao, C., Zhang, Y., Yuan, H., Yang, F., & Li, Q. (2025). Targeting Hsp90α to inhibit HMGB1‐mediated renal inflammation and fibrosis. Cell Proliferation. https://doi.org/10.1111/cpr.13774

Vancouver

Wei H, Ren J, Feng X, Zhao C, Zhang Y, Yuan H, et al. Targeting Hsp90α to inhibit HMGB1‐mediated renal inflammation and fibrosis. Cell Proliferation. 2025. doi:10.1111/cpr.13774

BibTeX
@article{Wei2025,
  author = {Wei, Huizhi and Ren, Jinhong and Feng, Xiue and Zhao, Chengxiao and Zhang, Yuanlin and Yuan, Hongxia and Yang, Fan and Li, Qingshan},
  title = {Targeting Hsp90α to inhibit HMGB1‐mediated renal inflammation and fibrosis},
  journal = {Cell Proliferation},
  year = {2025},
  doi = {10.1111/cpr.13774}
}
Kostenlos starten →